1. Home
  2. NVCR vs TAC Comparison

NVCR vs TAC Comparison

Compare NVCR & TAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NVCR
  • TAC
  • Stock Information
  • Founded
  • NVCR 2000
  • TAC 1909
  • Country
  • NVCR Switzerland
  • TAC Canada
  • Employees
  • NVCR N/A
  • TAC N/A
  • Industry
  • NVCR Medical/Dental Instruments
  • TAC Electric Utilities: Central
  • Sector
  • NVCR Health Care
  • TAC Utilities
  • Exchange
  • NVCR Nasdaq
  • TAC Nasdaq
  • Market Cap
  • NVCR 1.9B
  • TAC 2.9B
  • IPO Year
  • NVCR 2015
  • TAC N/A
  • Fundamental
  • Price
  • NVCR $17.71
  • TAC $10.99
  • Analyst Decision
  • NVCR Buy
  • TAC Buy
  • Analyst Count
  • NVCR 6
  • TAC 2
  • Target Price
  • NVCR $32.83
  • TAC $19.75
  • AVG Volume (30 Days)
  • NVCR 1.6M
  • TAC 1.7M
  • Earning Date
  • NVCR 07-24-2025
  • TAC 08-01-2025
  • Dividend Yield
  • NVCR N/A
  • TAC 1.60%
  • EPS Growth
  • NVCR N/A
  • TAC N/A
  • EPS
  • NVCR N/A
  • TAC 0.00
  • Revenue
  • NVCR $621,711,000.00
  • TAC $1,847,844,992.00
  • Revenue This Year
  • NVCR $5.56
  • TAC N/A
  • Revenue Next Year
  • NVCR $9.19
  • TAC N/A
  • P/E Ratio
  • NVCR N/A
  • TAC $4,540.66
  • Revenue Growth
  • NVCR 18.27
  • TAC N/A
  • 52 Week Low
  • NVCR $14.17
  • TAC $6.78
  • 52 Week High
  • NVCR $34.13
  • TAC $14.64
  • Technical
  • Relative Strength Index (RSI)
  • NVCR 51.32
  • TAC 54.64
  • Support Level
  • NVCR $17.53
  • TAC $10.59
  • Resistance Level
  • NVCR $18.70
  • TAC $10.91
  • Average True Range (ATR)
  • NVCR 0.72
  • TAC 0.25
  • MACD
  • NVCR 0.09
  • TAC -0.11
  • Stochastic Oscillator
  • NVCR 60.56
  • TAC 13.30

About NVCR NovoCure Limited

NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.

About TAC TransAlta Corporation

TransAlta Corp is an independent power producer based in Alberta, Canada. The company operates a diverse and growing fleet of electrical power generation assets in Canada, the United States, and Australia. The company has six reportable segments namely, Hydro, Wind & Solar, Energy Marketing, Gas, Energy Transition segment and Corporate Segment. The company generates the majority of its revenue from the gas segment.

Share on Social Networks: